Conjugated Estrogen sodium | CAS# 12126-59-9 | estrogen (hypoestrogenism)

MedKoo Cat#: 581229 | Name: Conjugated Estrogen sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Estrogens, conjugated is a pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. Conjugated estrogens are a medicine that contains a mixture of estrogen hormones. It is used to treat moderate to severe hot flashes, changes in and around the vagina, and other symptoms of menopause or low amounts of estrogen (hypoestrogenism). This medicine is also used to prevent osteoporosis (thinning of the bones) after menopause. Conjugated estrogens tablet is also used to treat symptoms of breast and prostate cancer that have spread through the body in men and women. It is also used to treat certain conditions in women before menopause if their ovaries do not make enough estrogen naturally.

Chemical Structure

Conjugated Estrogen sodium

CAS#12126-59-9

Theoretical Analysis

MedKoo Cat#: 581229

Name: Conjugated Estrogen sodium

CAS#: 12126-59-9

Chemical Formula: C18H19NaO5S

Exact Mass: 370.0851

Molecular Weight: 370.39

Elemental Analysis: C, 58.37; H, 5.17; Na, 6.21; O, 21.60; S, 8.66

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Estrogens, conjugated; Conjugated estrogens; TAG-39; TAG39; TAG 39; Conest; Kestrin; Conjugen;

IUPAC/Chemical Name

sodium (9S,13S,14S)-13-methyl-17-oxo-9,11,12,13,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate

InChi Key

QTTMOCOWZLSYSV-QWAPEVOJSA-M

InChi Code

InChI=1S/C18H20O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3-5,10,14,16H,2,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,16+,18+;/m1./s1

SMILES Code

O=S(OC(C=C1CC=C2[C@]3([H])CC4)=CC=C1[C@@]2([H])CC[C@]3(C)C4=O)([O-])=O.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 370.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sharifi M, Lewiecki EM. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev Clin Pharmacol. 2014 May;7(3):281-91. doi: 10.1586/17512433.2014.893819. Epub 2014 Mar 3. Review. PubMed PMID: 24580081. 2: Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S, Archer DF; SMART-5 Investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014 Feb;99(2):E189-98. doi: 10.1210/jc.2013-1707. Epub 2014 Jan 17. PubMed PMID: 24438370. 3: Levy MJ, Boyne MT 2nd, Rogstad S, Skanchy DJ, Jiang X, Geerlof-Vidavsky I. Marketplace Analysis of Conjugated Estrogens: Determining the Consistently Present Steroidal Content with LC-MS. AAPS J. 2015 Nov;17(6):1438-45. doi: 10.1208/s12248-015-9805-x. Epub 2015 Aug 5. PubMed PMID: 26242210; PubMed Central PMCID: PMC4627451. 4: Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis. Med Lett Drugs Ther. 2014 Apr 28;56(1441):33-4. PubMed PMID: 24759293. 5: Mirkin S, Komm BS, Pickar JH. Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data. Expert Opin Drug Saf. 2014 Jan;13(1):45-56. doi: 10.1517/14740338.2013.824965. Epub 2013 Aug 7. Review. PubMed PMID: 23919270. 6: Hussar DA, Purzycki DJ. Dapagliflozin propanediol, avanafil, and conjugated estrogens/bazedoxifene. J Am Pharm Assoc (2003). 2014 May-Jun;54(3):314; 316-8. doi: 10.1331/JAPhA.2014.14517. PubMed PMID: 24816359. 7: Barrera J, Chambliss KL, Ahmed M, Tanigaki K, Thompson B, McDonald JG, Mineo C, Shaul PW. Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract. Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E345-54. doi: 10.1152/ajpendo.00653.2013. Epub 2014 Jun 17. PubMed PMID: 24939737. 8: Pinkerton JV, Komm BS, Mirkin S. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model. Climacteric. 2013 Dec;16(6):618-28. doi: 10.3109/13697137.2013.810437. Epub 2013 Jun 27. Review. PubMed PMID: 23805785. 9: Palacios S, Mejía Ríos A. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women. Drugs Today (Barc). 2015 Feb;51(2):107-16. doi: 10.1358/dot.2015.51.2.2281023. Review. PubMed PMID: 25756066. 10: Pickar JH, Komm BS. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Post Reprod Health. 2015 Sep;21(3):112-21. doi: 10.1177/2053369115599090. Epub 2015 Aug 19. Review. PubMed PMID: 26289836. 11: Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Racketa J, Shi H, Chines AA, Mirkin S. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. J Womens Health (Larchmt). 2014 Jan;23(1):18-28. doi: 10.1089/jwh.2013.4392. Epub 2013 Nov 9. PubMed PMID: 24206058. 12: Goldstein SR. Still another selective estrogen receptor modulator to enhance women's health: this time in combination with conjugated equine estrogens. Menopause. 2014 Jan;21(1):1-2. doi: 10.1097/GME.0000000000000174. PubMed PMID: 24326285. 13: Brown S. Estradiol associated with lower thrombotic risk than conjugated equine estrogens when used as oral HRT. Menopause Int. 2013 Dec;19(4):145. PubMed PMID: 24479171. 14: Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol. 2014 Jul;142:16-29. doi: 10.1016/j.jsbmb.2013.10.011. Epub 2013 Oct 28. Review. PubMed PMID: 24176763. 15: Liu JH, Reape KZ, Hait HI. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2012 Jan;119(1):78-84. doi: 10.1097/AOG.0b013e31823c0145. PubMed PMID: 22183214. 16: Pinkerton JV, Pickar JH, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric. 2012 Oct;15(5):411-8. doi: 10.3109/13697137.2012.696289. Epub 2012 Aug 1. Review. PubMed PMID: 22853444. 17: Palacios S, Arias L, Lavenberg J, Pan K, Mirkin S, Komm BS. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population. Climacteric. 2016 Jun;19(3):261-7. doi: 10.3109/13697137.2016.1146248. Epub 2016 Mar 3. PubMed PMID: 26940720. 18: Black D, Messig M, Yu CR, Assaf AR, Komm BS, Mirkin S, Boucher M. The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials. Menopause. 2016 Apr;23(4):376-82. doi: 10.1097/GME.0000000000000541. PubMed PMID: 26694733. 19: Ma L, Yates SR, Ashworth D. Parent and conjugated estrogens and progestagens in surface water of the Santa Ana River: Determination, occurrence, and risk assessment. Environ Toxicol Chem. 2016 Nov;35(11):2657-2664. doi: 10.1002/etc.3447. Epub 2016 Jun 28. PubMed PMID: 27061433. 20: Zhang H, Shi J, Liu X, Zhan X, Chen Q. Occurrence and removal of free estrogens, conjugated estrogens, and bisphenol A in manure treatment facilities in East China. Water Res. 2014 Jul 1;58:248-57. doi: 10.1016/j.watres.2014.03.074. Epub 2014 Apr 13. PubMed PMID: 24768704.